ITUS Corporation (NYSE:ANIX) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a 12-month consensus price objective of $8.13 for the company, according to Zacks. Zacks has also assigned ITUS an industry rank of 83 out of 255 based on the ratings given to its competitors.
Separately, B. Riley reiterated a “buy” rating on shares of ITUS in a research report on Wednesday, October 3rd.
ITUS (NYSE:ANIX) last released its quarterly earnings results on Friday, September 7th. The company reported ($0.30) earnings per share for the quarter. The business had revenue of $0.36 million for the quarter.
In other ITUS news, CEO Amit Kumar purchased 11,000 shares of the firm’s stock in a transaction on Thursday, October 25th. The shares were acquired at an average cost of $3.90 per share, for a total transaction of $42,900.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
ITUS Company Profile
Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.
Featured Article: What are Closed-End Mutual Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.